Skip to main content

CorMedix, Inc. (CRMD)

NASDAQ: CRMD · Delayed Price · USD
4.91
-0.16 (-3.16%)
At close: Nov 29, 2021 4:00 PM
4.97
0.06 (1.22%)
After-hours:Nov 29, 2021 6:41 PM EST

Company Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.

It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.

The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix, Inc.
CountryUnited States
Founded2006
IPO DateMar 25, 2010
IndustryPharmaceuticals
SectorHealth Care
Employees35
CEOKhoso Baluch

Contact Details

Address:
400 Connell Dr Ste 5000
Berkeley Heights, New Jersey 07922-2809
United States
Phone908 517 9500
Websitecormedix.com

Stock Details

Ticker SymbolCRMD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001410098

Key Executives

NamePosition
Dr. Matthew T. David M.D.Interim Chief Executive Officer, Executive Vice President and Chief Financial Officer
Dr. Phoebe Mounts Esq.Executive Vice President, General Counsel, Secretary and Head of Regulatory, Compliance and Legal
Elizabeth Masson-HurlburtExecutive Vice President and Head of Clinical Operations
Dr. Paul Chew M.D.Acting Chief Medical Officer
Thomas NusbickelExecutive Vice President and Chief Commercial Officer

Latest SEC Filings

DateTypeTitle
Nov 19, 20214Statement of changes in beneficial ownership of securities
Nov 19, 20214Statement of changes in beneficial ownership of securities
Nov 10, 20214Statement of changes in beneficial ownership of securities
Nov 9, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 9, 20218-KCurrent report
Nov 3, 20214Statement of changes in beneficial ownership of securities
Oct 29, 2021DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 29, 2021DEF 14AOther definitive proxy statements
Oct 29, 20218-KCurrent report
Oct 4, 20218-KCurrent report
View All SEC Filings